The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Clinical Trial Update

21 Aug 2015 07:00

RNS Number : 6858W
4d Pharma PLC
21 August 2015
 

4D pharma plc

(the "Company" or "4D")

Clinical Trial Update

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announced today that it has commenced dosing in a phase 1 clinical trial for the treatment of Irritable bowel syndrome (IBS).

IBS is a functional bowel disorder characterised by discomfort, pain and changes in bowel habits. Symptoms can be mild, moderate or severe. Mild symptoms, which occur infrequently, can sometimes interfere with normal daily functioning. Moderate symptoms are more intense, occur more frequently, and often interfere with daily functioning. Severe symptoms chronically interfere with daily functioning. It is estimated that 10-15% of the population have IBS, with only 30-35% of patients seeking medical attention, the majority of which have persistent symptoms. There are currently few approved treatment options, all of which focus on the modulation of symptoms.

The clinical trial will assess the safety and tolerability of Blautix in a number of healthy volunteers and individuals with IBS. In addition, clinical symptoms and biomarkers relevant to the mechanism of action of Blautix will be assessed. The trial is expected to be completed in late 2015.

Dr. Alex Stevenson, 4D pharma's Chief Scientific Officer commented: "Having obtained regulatory and ethical approval for the Blautix clinical trial, dosing of the first subjects represents an important milestone in the development of the Live Biotherapeutics class. Blautix has been designed to treat the underlying cause of IBS, rather than just the symptoms and we look forward to assessing its effects in a clinical setting."

For further information please contact:

4D

+ 44 (0) 161 837 6205

Alex Stevenson, Chief Scientific Officer

 

Zeus Capital Limited - Nomad and Broker

Dan Bate/Ross Andrews

+44 (0) 161 831 1512

Dominic Wilson

+44 (0) 20 7533 7727

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRLLFIATVIIFIE
Date   Source Headline
18th Mar 20204:39 pmRNSPrice Monitoring Extension
18th Mar 20207:49 amRNSDirector/PDMR Shareholding
17th Mar 20207:00 amRNSAdditional Interim Clinical Data
16th Mar 20207:00 amRNSParticipation in Chardan Conference
11th Mar 20209:49 amRNSHolding(s) in Company
11th Mar 20207:00 amRNSHolding(s) in Company
9th Mar 202011:07 amRNSResult of Meeting
21st Feb 20202:25 pmRNSHolding(s) in Company
19th Feb 20202:06 pmRNSPosting of Circular
18th Feb 20206:28 pmRNSResult of Placing
18th Feb 20207:00 amRNSLaunch of Placing
7th Feb 20203:18 pmRNSHolding(s) in Company
6th Jan 20207:00 amRNSClinical Update
4th Dec 201911:22 amRNSHolding(s) in Company
29th Nov 201911:19 amRNSHolding(s) in Company
8th Nov 201911:27 amRNSHolding(s) in Company
6th Nov 20197:00 amRNSClinical Observations from MRx0518
5th Nov 20195:36 pmRNSHolding(s) in Company
4th Nov 201912:22 pmRNSHolding(s) in Company
4th Nov 201912:04 pmRNSHolding(s) in Company
17th Oct 201911:17 amRNSHolding(s) in Company
15th Oct 20192:51 pmRNSHolding(s) in Company
8th Oct 20197:00 amRNSCollaboration with MSD
30th Sep 20197:00 amRNSInterim Results
27th Sep 201912:23 pmRNSHolding(s) in Company
26th Sep 201911:40 amRNSHolding(s) in Company
23rd Sep 20197:00 amRNSPublication of data on neurodegenerative disease
20th Sep 20191:28 pmRNSHolding(s) in Company
20th Sep 20191:19 pmRNSHolding(s) in Company
20th Sep 201911:20 amRNSHolding(s) in Company
27th Aug 20197:00 amRNSAppointment of NED
25th Jul 20197:00 amRNSOncology Programmes Update
8th Jul 20193:51 pmRNSHolding(s) in Company
8th Jul 20197:00 amRNSClinical Update
1st Jul 20197:00 amRNSChange of Adviser
20th Jun 201910:38 amRNSResult of AGM
3rd Jun 20197:00 amRNS4D presents MRx0518 combination study at ASCO
30th May 20197:00 amRNSDirector/PDMR Shareholding
28th May 20192:50 pmRNSAnnual Report and Notice of AGM
23rd May 20197:00 amRNSDirector/PDMR Shareholding
22nd May 20197:00 amRNSDirector/PDMR Shareholding
21st May 20197:00 amRNSFinal Results
16th May 20197:00 amRNS4D Presents Phase Ib Clinical Data on Thetanix®
13th May 20198:00 amRNSParticipation in Conferences
29th Apr 20197:00 amRNSClinical Update - MRx0518 oncology programmes
14th Mar 20197:00 amRNSDirector/PDMR Shareholding
13th Mar 20199:08 amRNSDirector/PDMR Shareholding
8th Mar 20197:00 amRNSParticipation in Microbiome Conference
29th Jan 20197:00 amRNSPublication of data in connection with MRx0518
7th Jan 20197:00 amRNSCollaboration with MD Anderson Cancer Center

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.